Clinical Trial: A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559175) titled 'A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.' on March 26.

Brief Summary: The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep(R)) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep(R) are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all o...